Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Atacicept in Active Lupus Nephritis
2022-000257-83Phase 3Active
- Sponsor
- Vera Therapeutics
- Start
- Aug 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Atacicept weekly SC with Placebo weekly SC (2 arms). Started Aug 2022; status: active.
02
Drugs
atacicept
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2022-000257-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000257-83.